MindBio Therapeutics is a clinical stage drug development company that is pioneering psychedelic microdosing. With its first candidate drug LSD currently in Phase 1 clinical trials microdosing LSD in 80 healthy participants. In a world first clinical trial of its kind, participants are prescribed the microdoses of LSD to take home with them after receiving a battery of psychological and biometric baseline tests in the laboratory. Phase 2 clinical trials microdosing LSD have just been approved in late stage cancer patients experiencing existential distress, anxiety and depression. MindBio Therapeutics has a unique drug formulation strategy that will integrate with artificial intelligence and technology development for the enhanced safety, optimal dosing and monitoring of patients. The Phase 1 clinical trials involve a randomised, double-blind, placebo-controlled trial to study the effects of repeated microdoses of lysergic acid diethylamide (LSD) on creativity and brain activity in healthy adults. The Phase 2 clinical trials for cancer patients will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted – Meaning Centred Psychotherapy to standard Meaning-Centred Psychotherapy in people who have advanced cancer and anxiety or depression. Participants will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo. The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. Our findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer.